March 27, 2017
Shionogi said its peripherally-acting mu-opioid receptor antagonist naldemedine was approved by the US FDA on March 23 for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. The drug is expected to be available in the...read more